• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plc

    5/7/25 9:00:03 AM ET
    $AUTL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AUTL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    Autolus Therapeutics plc

    (Name of Issuer)


    Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

    (Title of Class of Securities)


    05280R100

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    05280R100


    1Names of Reporting Persons

    Syncona Portfolio Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    GUERNSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    28,821,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    28,821,053.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    28,821,053.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Response to Items 6, 8 and 9 consist of 12,180,333 ordinary shares and 16,640,720 American Depositary Shares ("ADSs") held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer. The ordinary shares and the ADSs are collectively referred to as the "Ordinary Shares". Response to Item 11 is based on 266,128,900 Ordinary Shares outstanding as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 20, 2025.


    SCHEDULE 13G

    CUSIP No.
    05280R100


    1Names of Reporting Persons

    Syncona Holdings Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    GUERNSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    28,821,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    28,821,053.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    28,821,053.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Response to Items 6, 8 and 9 consist of 12,180,333 ordinary shares and 16,640,720 American Depositary Shares ("ADSs") held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer. The ordinary shares and the ADSs are collectively referred to as the "Ordinary Shares". Response to Item 11 is based on 266,128,900 Ordinary Shares outstanding as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 20, 2025.


    SCHEDULE 13G

    CUSIP No.
    05280R100


    1Names of Reporting Persons

    Syncona Investment Management Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    28,821,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    28,821,053.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    28,821,053.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Response to Items 6, 8 and 9 consist of 12,180,333 ordinary shares and 16,640,720 American Depositary Shares ("ADSs") held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer. The ordinary shares and the ADSs are collectively referred to as the "Ordinary Shares". Response to Item 11 is based on 266,128,900 Ordinary Shares outstanding as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 20, 2025.


    SCHEDULE 13G

    CUSIP No.
    05280R100


    1Names of Reporting Persons

    Syncona Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    GUERNSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    28,821,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    28,821,053.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    28,821,053.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Response to Items 6, 8 and 9 consist of 12,180,333 ordinary shares and 16,640,720 American Depositary Shares ("ADSs") held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer. The ordinary shares and the ADSs are collectively referred to as the "Ordinary Shares". Response to Item 11 is based on 266,128,900 Ordinary Shares outstanding as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 20, 2025.


    SCHEDULE 13G

    CUSIP No.
    05280R100


    1Names of Reporting Persons

    Roel Bulthuis
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    28,821,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    28,821,053.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    28,821,053.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Response to Items 6, 8 and 9 consist of 12,180,333 ordinary shares and 16,640,720 American Depositary Shares ("ADSs") held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer. The ordinary shares and the ADSs are collectively referred to as the "Ordinary Shares". Response to Item 11 is based on 266,128,900 Ordinary Shares outstanding as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 20, 2025.


    SCHEDULE 13G

    CUSIP No.
    05280R100


    1Names of Reporting Persons

    Christopher Hollowood
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    28,821,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    28,821,053.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    28,821,053.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Response to Items 6, 8 and 9 consist of 12,180,333 ordinary shares and 16,640,720 American Depositary Shares ("ADSs") held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer. The ordinary shares and the ADSs are collectively referred to as the "Ordinary Shares". Response to Item 11 is based on 266,128,900 Ordinary Shares outstanding as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 20, 2025.


    SCHEDULE 13G

    CUSIP No.
    05280R100


    1Names of Reporting Persons

    Kenneth Galbraith
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    28,821,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    28,821,053.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    28,821,053.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Response to Items 6, 8 and 9 consist of 12,180,333 ordinary shares and 16,640,720 American Depositary Shares ("ADSs") held directly by Syncona Portfolio Limited. Each ADS represents one ordinary share, nominal value $0.000042 per share, of the Issuer. The ordinary shares and the ADSs are collectively referred to as the "Ordinary Shares". Response to Item 11 is based on 266,128,900 Ordinary Shares outstanding as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 20, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Autolus Therapeutics plc
    (b)Address of issuer's principal executive offices:

    The Mediaworks, 191 Wood Lane, London W12 7FP, United Kingdom
    Item 2. 
    (a)Name of person filing:

    (i) Syncona Portfolio Limited; (ii) Syncona Holdings Limited; (iii)Syncona Investment Management Limited; (iv) Syncona Limited; (v) Roel Bulthuis; (vi) Christopher Hollowood; and (vii) Kenneth Galbraith
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited is Frances House, PO Box 273, Sir William Place, St. Peter Port, Guernsey, GY1 3RD, Channel Islands. The address of the principal business office of Syncona Investment Management Limited, Roel Bulthuis, Christopher Hollowood and Kenneth Galbraith is 2nd Floor, 8 Bloomsbury Street, London WC1B 3SR, United Kingdom.
    (c)Citizenship:

    Syncona Portfolio Limited, Syncona Holdings Limited and Syncona Limited's citizenship is Guernsey. Syncona Investment Management Limited and Christopher Hollowood's citizenship is United Kingdom. Roel Bulthuis' citizenship is the Netherlands. Kenneth Galbraith's citizenship is Canada.
    (d)Title of class of securities:

    Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
    (e)CUSIP No.:

    05280R100
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    28,821,053
    (b)Percent of class:

    10.8  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    28,821,053

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    28,821,053

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Syncona Portfolio Limited
     
    Signature:/s/ Nicholas Moss
    Name/Title:Nicholas Moss, Director
    Date:05/07/2025
     
    Syncona Holdings Limited
     
    Signature:/s/ Nicholas Moss
    Name/Title:Nicholas Moss, Director
    Date:05/07/2025
     
    Syncona Investment Management Limited
     
    Signature:/s/ Christopher Hollowood
    Name/Title:Christopher Hollowood
    Date:05/07/2025
     
    Syncona Limited
     
    Signature:/s/ Robert Hutchinson
    Name/Title:Robert Hutchinson
    Date:05/07/2025
     
    Roel Bulthuis
     
    Signature:/s/ Roel Bulthuis
    Name/Title:Roel Bulthuis
    Date:05/07/2025
     
    Christopher Hollowood
     
    Signature:/s/ Christopher Hollowood
    Name/Title:Christopher Hollowood
    Date:05/07/2025
     
    Kenneth Galbraith
     
    Signature:/s/ Kenneth Galbraith
    Name/Title:Kenneth Galbraith
    Date:05/07/2025
    Get the next $AUTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AUTL

    DatePrice TargetRatingAnalyst
    11/18/2024$7.00 → $7.60Neutral → Buy
    Goldman
    11/15/2024$13.00Neutral → Buy
    Redburn Atlantic
    11/9/2023$10.00Buy
    Deutsche Bank
    3/27/2023$8.00Overweight
    Wells Fargo
    3/17/2023$5.00Buy
    Bryan Garnier
    More analyst ratings

    $AUTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

      SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

      11/14/24 4:32:31 PM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

      SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

      11/14/24 1:44:27 PM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Autolus Therapeutics plc

      SC 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

      11/14/24 9:12:16 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AUTL
    Financials

    Live finance-specific insights

    See more
    • Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

      Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 millionU.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) initiating before year-end 2025Conference call to be held today at 08:30 am EDT/13:30 pm GMT: conference call participants should pre-register usin

      5/8/25 7:00:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

      Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) and multiple sclerosis (MS)Preliminary data in initial six patient cohort treated in Phase 1 trial in systemic lupus erythematosus (SLE) support progressing obe-cel into a planned Phase 2 pivotal study in lupus nephritis; first patient expected to be dosed in Phase 2 trial by year-end 2025Company plans to advance obe-cel in progressive forms of multiple sclerosis (MS); first patient expected to be dosed in Phase 1 trial by year-end 2025 LONDON, April 23, 2025 (GLOBE NEWSWIRE) -- Autolus Therap

      4/23/25 4:05:00 PM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and operational highlights before open of US markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conferenc

      4/22/25 7:00:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AUTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

      LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Oral S113: Title: Can CAR T-cell therapy be a definitive treatment for ad

      5/14/25 9:30:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

      Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 millionU.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) initiating before year-end 2025Conference call to be held today at 08:30 am EDT/13:30 pm GMT: conference call participants should pre-register usin

      5/8/25 7:00:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

      UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autoleucel in adult patients with r/r B-ALL1AUCATZYL® licensed from MHRA under ‘conditional marketing authorisation', meaning that the MHRA will review new efficacy and safety information at least once every year1 Investors, US and UK National, Medical and Industry media only LONDON, April 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces today that the UK Medicines and Healthcare products

      4/25/25 12:06:39 PM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AUTL
    SEC Filings

    See more
    • SEC Form EFFECT filed by Autolus Therapeutics plc

      EFFECT - Autolus Therapeutics plc (0001730463) (Filer)

      5/16/25 12:15:27 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by Autolus Therapeutics plc

      424B3 - Autolus Therapeutics plc (0001730463) (Filer)

      5/15/25 4:13:24 PM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plc

      SCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)

      5/12/25 10:24:40 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AUTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Autolus Therapeutics upgraded by Goldman with a new price target

      Goldman upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $7.60 from $7.00 previously

      11/18/24 7:38:09 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded Autolus Therapeutics from Neutral to Buy and set a new price target of $13.00

      11/15/24 7:30:20 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Autolus Therapeutics with a new price target

      Deutsche Bank initiated coverage of Autolus Therapeutics with a rating of Buy and set a new price target of $10.00

      11/9/23 6:38:44 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AUTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

      Innate to propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to a CEO/board of directors Irina Staatz-Granzer, current Chairwoman of the Supervisory board would be appointed Chairwoman of the board of Directors Jonathan Dickinson, current Chairman of the Executive board would be appointed Chief Executive Officer and named to the board of Directors Two new members would join the board of Directors Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from

      4/16/25 1:00:00 AM ET
      $AUTL
      $IPHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

      LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief Development Officer. Dr. Will is joining Autolus' executive team and will lead the company's development organization effective September 30, 2024. "Matthias has a proven track record of success in pharmaceutical product development, achieving many key regulatory milestones and marketing approvals across several cancer indications," said Dr. Christian Itin, Chief Executive Officer of Autolus. "His in-depth development experience and leadership skil

      9/19/24 7:00:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Autolus Therapeutics Announces Changes to its Board of Directors

      LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive Director. John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director. These changes are effective as of today, April 1, 2024. "On behalf of the Board and Management team, we would like to thank John for his leadership during a transformational period for the Company, which included conducting the pivotal Phase 2 FELIX study and th

      4/1/24 7:00:00 AM ET
      $AUTL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care